Agilent Technologies acquires Biocare Medical for USD950M to expand its pathology portfolio

USA—Agilent Technologies has agreed to acquire Biocare Medical, a pathology solutions provider, in an all-cash transaction valued at USD 950 million.

The deal will give the life sciences company control of Biocare’s specialized diagnostic technologies used in cancer detection and clinical pathology.

California-based Biocare brings a robust portfolio of immunohistochemistry (IHC), in situ hybridization (ISH), and fluorescence in situ hybridization (FISH) solutions to the table.

These technologies play a critical role in oncology diagnostics and broader pathology applications, helping clinicians deliver better patient outcomes.

Strategic combination creates expanded market reach

Agilent expects the merger to create a more powerful platform for serving both research and clinical customers worldwide.

By combining its global operations with Biocare’s established commercial presence across the United States, the company aims to reach a wider customer base and strengthen its market position.

Biocare’s extensive catalog includes more than 300 specialized antibodies, which will significantly enhance Agilent’s capabilities in developing and commercializing new in vitro diagnostic (IVD) antibodies.

This expanded product range positions Agilent to accelerate innovation in the pathology diagnostics space.

Financial projections and integration timeline

The transaction is expected to close during the fourth quarter of Agilent’s 2026 fiscal year, pending regulatory approvals and customary closing conditions.

Agilent anticipates the acquisition will boost its earnings per share approximately one year after completion.

Following the deal’s closure, Biocare will integrate into Agilent’s Life Sciences and Diagnostics Markets Group (LDG) business segment.

During the first quarter of fiscal 2026, this division generated USD679 million in revenue, representing a 5% year-over-year increase.

Leadership perspectives on growth strategy

Agilent CEO Padraig McDonnell emphasized that acquiring Biocare aligns with the company’s broader strategy of driving long-term growth through customer-focused innovation and careful capital deployment.

He noted that the complementary nature of the two organizations will enable Agilent to better serve pathology customers across both clinical and research environments while accelerating innovation and creating shareholder value.

Biocare’s track record under private equity

Venture capital firms Excellere Partners and GHO Capital have owned Biocare since 2021, during which time the company achieved consecutive years of double-digit growth.

In 2025 alone, Biocare generated USD 90 million in revenue, demonstrating strong market demand for its products.

Biocare CEO Luiz de Luzuriaga stated that after years of substantial progress, the timing is ideal to transition to new ownership that shares the company’s dedication to product quality, clinical impact, and value creation.

Second major acquisition in two years

If completed, this deal will mark Agilent’s second significant acquisition in consecutive years.

In September 2024, the company finalized a USD 925 million purchase of BIOVECTRA, a Canadian contract development and manufacturing organization (CDMO), demonstrating its ongoing commitment to strategic expansion through targeted acquisitions.